老年高血压降压指南PPT课件.ppt

* After screening, patients are included either in the ONTARGET - or the TRANSCEND trial. ONTARGET patients are titrated to telmisartan 80 mg/day, or ramipril 10 mg/day, or a combination of telmisartan 80 mg/day and ramipril 10 mg/day (receiving matching placebos in the monotherapy groups). In the TRANSCEND trial, telmisartan 80 mg/day is tested against placebo. Both trials have a follow-up period of 5.5 years. * * * * * * * * * * * * * * * * * * 随机到活性药物治疗组的患者接受雅施达4mg/日的治疗。由经治医生决定是否加用纳催离以达到理想降压目标。 * * Time to Primary Outcome ONTARGET ONTARGET: Primary Outcome  HOPE Primary Outcome Ram Tel Te